EMA Needs More Cases To Assess Value Of Involving Patients In CHMP Meetings
This article was originally published in SRA
Executive Summary
The European Medicines Agency is extending an ongoing pilot project in which it invites patients to take part in certain meetings that its human medicines committee, the CHMP, holds to discuss the benefits and risks of drugs.
You may also be interested in...
Pharma Firms Told To ‘Keep Your Distance’ When Patients Come To EU CHMP Meetings
The European Medicines Agency is planning to expand the involvement of patients in benefit-risk evaluation of medicines following a successful pilot, but one EU patient group has advised drug companies not to contact patients during their visits to the agency as this could lower the value of their input.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.